Search Results - "Raghav, Kanwal P S"

Clinical and molecular characterization of early‐onset colorectal cancer by Willauer, Alexandra N., Liu, Yusha, Pereira, Allan A. L., Lam, Michael, Morris, Jeffrey S., Raghav, Kanwal P. S., Morris, Van K., Menter, David, Broaddus, Russell, Meric‐Bernstam, Funda, Hayes‐Jordan, Andrea, Huh, Winston, Overman, Michael J., Kopetz, Scott, Loree, Jonathan M.

“…Background Colorectal cancer (CRC) incidence is increasing in adults younger than 50 years. This study evaluated clinical and molecular features to identify…”
Get full text

Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial by Shroff, Rachna T, Javle, Milind M, Xiao, Lianchun, Kaseb, Ahmed O, Varadhachary, Gauri R, Wolff, Robert A, Raghav, Kanwal P S, Iwasaki, Michiko, Masci, Peter, Ramanathan, Ramesh K, Ahn, Daniel H, Bekaii-Saab, Tanios S, Borad, Mitesh J

“…Administration of gemcitabine-cisplatin, the current standard therapy for advanced biliary tract cancers, results in median progression-free survival and…”
Get more information

Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers by Raghav, Kanwal P. S., Hernandez‐Aya, Leonel F., Lei, Xiudong, Chavez‐MacGregor, Marianan, Meric‐Bernstam, Funda, Buchholz, Thomas A., Sahin, Aysegul, Do, Kim‐Anh, Hortobagyi, Gabriel N., Gonzalez‐Angulo, Ana M.

“…PURPOSE: To evaluate the impact of low estrogen/progesterone receptor (ER/PR) expression and effect of endocrine therapy on survival outcomes in human…”
Get full text

Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older by Mizrahi, Jonathan D., Rogers, Jane E., Hess, Kenneth R., Wolff, Robert A., Varadhachary, Gauri R., Javle, Milind M., Shroff, Rachna T., Ho, Linus, Fogelman, David R., Raghav, Kanwal P.S., Overman, Michael J., Pant, Shubham

“…Although FOLFIRINOX (5-Fluorouracil + leucovorin + irinotecan + oxaliplatin) is now the standard of care for patients (pts) with metastatic pancreatic cancer…”
Get full text

Laparoscopic Partial Splenectomy for Unknown Primary Cancer: A Stepwise Approach by Vega, Eduardo A., Yamashita, Suguru, Shin, Chun Yun, Kim, Michael, Fleming, Jason B., Katz, Mathew H., Raghav, Kanwal P. S., Vauthey, Jean-Nicolas, Lee, Jeffrey E., Conrad, Claudius

“…Background Laparoscopic partial splenectomy (LPS) for focal splenic lesions is technically demanding and carries risk of hemorrhage. Nevertheless, it can be a…”
Get full text

Impact of Molecular Alterations and Targeted Therapy in Appendiceal Adenocarcinomas by Raghav, Kanwal P.S., Shetty, Aditya V., Kazmi, Syed M.A., Zhang, Nianxiang, Morris, Jeffrey, Taggart, Melissa, Fournier, Keith, Royal, Richard, Mansfield, Paul, Eng, Cathy, Wolff, Robert A., Overman, Michael J.

“…Background. Appendiceal adenocarcinomas (AAs) are rare and this has limited their molecular understanding. The purpose of our study was to characterize the…”
Get full text

Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma by Rogers, Jane E., Mizrahi, Jonathan D., Xiao, Lianchun, Mohindroo, Chirayu, Shroff, Rachna T., Wolff, Robert, Varadhachary, Gauri R., Javle, Milind M., Overman, Michael, Fogelman, David R., Raghav, Kanwal P. S., Pant, Shubham, McAllister, Florencia

“…Background Gemcitabine (GEM) plus nab‐paclitaxel (NabP) (GEM 1000 mg/m2 IV over 30 minutes + NabP 125 mg/m2 IV given days 1, 8, and 15 every 28 days) is one of…”
Get full text

Molecular Pathways and Mechanisms of HER2 in Cancer Therapy by Raghav, Kanwal P S, Moasser, Mark M

“…The oncogene ERBB2 encoding the receptor tyrosine-protein kinase erbB-2 (HER2) is frequently overexpressed or amplified and occasionally mutated in a variety…”
Get full text

PRESSING Need of Precision Care in HER2-Positive Colorectal Cancer: The ELEPHANT in the Room by Raghav, Kanwal P S, Loree, Jonathan M, Kopetz, Scott

“…Although dual HER2 inhibition has shown promising clinical activity in patients with RAS wild-type HER2-positive metastatic colorectal cancer, predictive…”
Get full text

Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors by Ludford, Kaysia, Ho, Won Jin, Thomas, Jane V, Raghav, Kanwal P S, Murphy, Mariela Blum, Fleming, Nicole D, Lee, Michael S, Smaglo, Brandon G, You, Y Nancy, Tillman, Matthew M, Kamiya-Matsuoka, Carlos, Thirumurthi, Selvi, Messick, Craig, Johnson, Benny, Vilar, Eduardo, Dasari, Arvind, Shin, Sarah, Hernandez, Alexei, Yuan, Xuan, Yang, Hongqui, Foo, Wai Chin, Qiao, Wei, Maru, Dipen, Kopetz, Scott, Overman, Michael J

“…Pembrolizumab significantly improves clinical outcomes in advanced/metastatic microsatellite instability high (MSI-H)/deficient mismatch repair (dMMR) solid…”
Get full text

Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma by Korphaisarn, Krittiya, Morris, Van, Davis, Jenifer S., Overman, Michael J., Fogelman, David R., Kee, Bryan K., Dasari, Arvind, Raghav, Kanwal P. S., Shureiqi, Imad, Trupti, Metha, Wolff, Robert A., Eng, Cathy, Menter, David G., Hamilton, Stanley, Kopetz, Scott

“…Background Signet ring cell carcinoma (SRCC) is a rare subtype of colorectal cancer (CRC). The aim of this study was to characterise the genomic alterations…”
Get full text

Endoscopic and imaging outcomes of PD-1 therapy in localised dMMR colorectal cancer by Fox, Daniel A., Bhamidipati, Deepak, Konishi, Tsuyoshi, Kaur, Harmeet, You, Nancy, Raghav, Kanwal P.S., Ge, Phillip S., Messick, Craig, Johnson, Benny, Morris, Van K., Thomas, Jane V., Shah, Preksha, Bednarski, Brian K., Kopetz, Scott, Chang, George J., Ludford, Kaysia, Higbie, Victoria Serpas, Overman, Michael J.

“…Neoadjuvant immune checkpoint blockade (IO) is emerging as a therapeutic option for patients with deficient mismatch repair (dMMR) colorectal cancer (CRC)…”
Get full text

Malignant Mesothelioma of the Peritoneum in Women: A Clinicopathologic Study of 164 Cases by Malpica, Anais, Euscher, Elizabeth D., Marques-Piubelli, Mario L., Ferrufino-Schmidt, Maria C., Miranda, Roberto N., Sams, Ralph, Royal, Richard E., Raghav, Kanwal P.S., Fournier, Keith F., Ramalingam, Preetha

“…Malignant mesothelioma of the peritoneum in women is an uncommon tumor. In this study, we present the clinicopathologic features of 164 such cases seen in our…”
Get full text

Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA by Kaseb, Ahmed O, Sánchez, Nora S, Sen, Shiraj, Kelley, Robin K, Tan, Benjamin, Bocobo, Andrea G, Lim, Kian H, Abdel-Wahab, Reham, Uemura, Marc, Pestana, Roberto Carmagnani, Qiao, Wei, Xiao, Lianchun, Morris, Jeffrey, Amin, Hesham M, Hassan, Manal M, Rashid, Asif, Banks, Kimberly C, Lanman, Richard B, Talasaz, AmirAli, Mills-Shaw, Kenna R, George, Bhawana, Haque, Abedul, Raghav, Kanwal P S, Wolff, Robert A, Yao, James C, Meric-Bernstam, Funda, Ikeda, Sadakatsu, Kurzrock, Razelle

“…Molecular profiling has been used to select patients for targeted therapy and determine prognosis. Noninvasive strategies are critical to hepatocellular…”
Get full text

CUP-AI-Dx: A tool for inferring cancer tissue of origin and molecular subtype using RNA gene-expression data and artificial intelligence by Zhao, Yue, Pan, Ziwei, Namburi, Sandeep, Pattison, Andrew, Posner, Atara, Balachander, Shiva, Paisie, Carolyn A., Reddi, Honey V, Rueter, Jens, Gill, Anthony J, Fox, Stephen, Raghav, Kanwal P.S., Flynn, William F, Tothill, Richard W., Li, Sheng, Karuturi, R. Krishna Murthy, George, Joshy

“…Cancer of unknown primary (CUP), representing approximately 3-5% of all malignancies, is defined as metastatic cancer where a primary site of origin cannot be…”
Get full text

Ablative liver radiotherapy for unresected intrahepatic cholangiocarcinoma: Patterns of care and survival in the United States by De, Brian, Tran Cao, Hop S., Vauthey, Jean‐Nicolas, Manzar, Gohar S., Corrigan, Kelsey L., Raghav, Kanwal P. S., Lee, Sunyoung S., Tzeng, Ching‐Wei D., Minsky, Bruce D., Smith, Grace L., Holliday, Emma B., Taniguchi, Cullen M., Koong, Albert C., Das, Prajnan, Javle, Milind, Ludmir, Ethan B., Koay, Eugene J.

“…Background Single‐institution studies have shown the oncologic benefit of ablative liver radiotherapy (A‐RT) for patients with unresectable intrahepatic…”
Get full text

Cancer of Unknown Primary Presenting as Bone‐Predominant or Lymph Node‐Only Disease: A Clinicopathologic Portrait by Huey, Ryan W., Smaglo, Brandon G., Estrella, Jeannelyn S., Matamoros, Aurelio, Overman, Michael J., Varadhachary, Gauri R., Raghav, Kanwal P.S.

“…Background Cancer of unknown primary (CUP) presenting as bone‐predominant (BCUP) or lymph node‐only disease (LNCUP) represents two clinically distinct subsets…”
Get full text

Significance of Distinct Liquid Biopsy Compartments in Evaluating Somatic Mutations for Targeted Therapy Selection in Cancer of Unknown Primary by Kolbinger, Fiona R., Bernard, Vincent, Lee, Jaewon J., Stephens, Bret M., Branchi, Vittorio, Raghav, Kanwal P. S., Maitra, Anirban, Guerrero, Paola A., Semaan, Alexander

“…Purpose Cancer of unknown primary (CUP) accounts for 2–5% of all cancer diagnoses, wherein standard investigations fail to reveal the original tumor site…”
Get full text

The role of HER2 amplification testing in metastatic colorectal cancer by Raghav, Kanwal P S

Get full text

Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie by Loree, Jonathan M, Kopetz, Scott, Raghav, Kanwal P S

“…While the treatment of colorectal cancer continues to rely heavily on conventional cytotoxic therapy, an increasing number of targeted agents are under…”
Get full text